Abstract
BACKGROUND: Spinal muscular atrophy is an autosomal recessive neuromuscular disorder that is caused by an insufficient level of survival motor neuron (SMN) protein. Nusinersen is an antisense oligonucleotide drug that modifies pre–messenger RNA splicing of the SMN2 gene and thus promotes increased production of full-length SMN protein. METHODS: We conducted a randomized, double-blind, sham-controlled, phase 3 efficacy and safety trial of nusinersen in infants with spinal muscular atrophy. The primary end points were a motor-milestone response (defined according to results on the Hammersmith Infant Neurological Examination) and event-free survival (time to death or the use of permanent assisted ventilation). Secondary end points included overall survival and subgroup analyses of event-free survival according to disease duration at screening. Only the first primary end point was tested in a prespecified interim analysis. To control the overall type I error rate at 0.05, a hierarchical testing strategy was used for the second primary end point and the secondary end points in the final analysis. RESULTS: In the interim analysis, a significantly higher percentage of infants in the nusinersen group than in the control group had a motor-milestone response (21 of 51 infants [41%] vs. 0 of 27 [0%], P<0.001), and this result prompted early termination of the trial. In the final analysis, a significantly higher percentage of infants in the nusinersen group than in the control group had a motor-milestone response (37 of 73 infants [51%] vs. 0 of 37 [0%]), and the likelihood of event-free survival was higher in the nusinersen group than in the control group (hazard ratio for death or the use of permanent assisted ventilation, 0.53; P=0.005). The likelihood of overall survival was higher in the nusinersen group than in the control group (hazard ratio for death, 0.37; P=0.004), and infants with a shorter disease duration at screening were more likely than those with a longer disease duration to benefit from nusinersen. The incidence and severity of adverse events were similar in the two groups. CONCLUSIONS: Among infants with spinal muscular atrophy, those who received nusinersen were more likely to be alive and have improvements in motor function than those in the control group. Early treatment may be necessary to maximize the benefit of the drug.
| Original language | English |
|---|---|
| Pages (from-to) | 1723-1732 |
| Number of pages | 10 |
| Journal | New England Journal of Medicine |
| Volume | 377 |
| Issue number | 18 |
| DOIs | |
| State | Published - Nov 2 2017 |
Fingerprint
Dive into the research topics of 'Nusinersen versus sham control in infantile-onset spinal muscular atrophy'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: New England Journal of Medicine, Vol. 377, No. 18, 02.11.2017, p. 1723-1732.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Nusinersen versus sham control in infantile-onset spinal muscular atrophy
AU - Finkel, Richard S.
AU - Mercuri, Eugenio
AU - Darras, Basil T.
AU - Connolly, Anne M.
AU - Kuntz, Nancy L.
AU - Kirschner, Janbernd
AU - Chiriboga, Claudia A.
AU - Saito, Kayoko
AU - Servais, Laurent
AU - Tizzano, Eduardo
AU - Topaloglu, Haluk
AU - Tulinius, Már
AU - Montes, Jacqueline
AU - Glanzman, Allan M.
AU - Bishop, Kathie
AU - Zhong, Z. John
AU - Gheuens, Sarah
AU - Bennett, C. Frank
AU - Schneider, Eugene
AU - Farwell, Wildon
AU - De Vivo, Darryl C.
AU - Bradley, W. G.
AU - Schroth, M. K.
AU - Bodensteriner, J. B.
AU - Davis, C. S.
AU - Shell, R.
AU - Hen, J.
AU - Austin, E. D.
AU - Aziz-Zaman, S.
AU - Cappell, J.
AU - Constantinescu, A.
AU - Cruz, R.
AU - Dastgir, J.
AU - Dunaway, S.
AU - Engelstad, K.
AU - Gormley, M.
AU - Holuba La Marca, N.
AU - Khandji, A.
AU - Kramer, S.
AU - Marra, J.
AU - Ortiz-Miller, C.
AU - Popolizio, M.
AU - Salazar, R.
AU - Sanabria, L.
AU - Weimer, L.
AU - Anand, P.
AU - Gadeken, R.
AU - Golumbek, P. T.
AU - Siener, C.
AU - Zaidman, C. M.
AU - Al-Ghamdi, F.
AU - Berde, C.
AU - Ghosh, P.
AU - Graham, R.
AU - Harrington, T.
AU - Koka, A.
AU - Laine, R.
AU - Liew, W.
AU - Mirek, E.
AU - Ordonez, G.
AU - Pasternak, A.
AU - Quigley, J.
AU - Sethna, N.
AU - Souris, M.
AU - Szelag, H.
AU - Wand, L.
AU - Day, J. W.
AU - D'Souza, G.
AU - Duong, T. T.
AU - Gee, R.
AU - Kitsuwa-Lowe, J.
AU - McFall, D.
AU - Patnaik, S.
AU - Paulose, S.
AU - Perez, J.
AU - Proud, C.
AU - Purse, B.
AU - Ramamurthi, R. J.
AU - Sakamuri, S.
AU - Sampson, J.
AU - Sanjanwala, B.
AU - Tesi Rocha, A. C.
AU - Watson, K.
AU - Welsh, L.
AU - Pena, L. D.M.
AU - Case, L.
AU - Coates, J.
AU - DeArmey, S.
AU - Homi, M. M.
AU - Milleson, C.
AU - Nelson, N.
AU - Ross, A.
AU - Smith, E.
AU - Taicher, B.
AU - Wootton, J.
AU - Finanger, E.
AU - Benjamin, D.
AU - Frank, A.
AU - Roberts, C.
AU - Russman, B.
AU - Zilke, K.
AU - Berry, D.
AU - Civitello, M.
AU - Cook, D.
AU - Endsley, J. D.
AU - Johnson, C.
AU - Kasper, M.
AU - Leon, W.
AU - Lim, A.
AU - O'Reardon, K.
AU - Sigurdardottir, L. Y.
AU - Turner, J.
AU - Weber-Guzman, F.
AU - Zinn, M.
AU - Iannaccone, S. T.
AU - Castro, D.
AU - Cowie, M.
AU - Farrow-Gillespie, A.
AU - Herbert, A.
AU - Kauk, M.
AU - McElroy, D.
AU - Miller, N.
AU - Nelson, L.
AU - Smith, L.
AU - Spain, T.
AU - Trest, S.
AU - Johnson, N.
AU - Butterfield, R.
AU - DiBella, D.
AU - Mayne, K.
AU - Newcomb, T. M.
AU - Rausch, N.
AU - Blomgren, C.
AU - Choi, H. W.
AU - Epstein, L.
AU - Goldman, S.
AU - Krosschell, K.
AU - Krueger, J.
AU - Kurz, J.
AU - Rao, V.
AU - Parsons, J.
AU - Allen, V.
AU - Bielsky, A.
AU - Booker, K.
AU - Camuto, A.
AU - Carry, T.
AU - Fuhr, P.
AU - Gibbons, M.
AU - Janas, J.
AU - Johnson, H.
AU - Kelly, C.
AU - Lord-Halvorson, L. S.
AU - Nicolarsen, S.
AU - Shea, S.
AU - Tran, V.
AU - VanderVeen, G.
AU - Yang, M.
AU - Zimmerman, C.
AU - Shieh, P.
AU - Parziale, N.
AU - Rao, L.
AU - Said, J. W.
AU - Shu, F.
AU - Skura, C.
AU - Staudt, L.
AU - Tennekoon, G.
AU - Adang, L.
AU - Brandsema, J.
AU - Chadehumbe, M.
AU - Flickinger, J.
AU - Kichula, E.
AU - Stanford, D.
AU - Toms, M.
AU - Zigmont, J.
AU - Oskoui, M.
AU - Arpin, S.
AU - Dinunzio, P.
AU - Ingelmo, P. M.
AU - Poulin, C.
AU - Rivera, G.
AU - Sabapathy, C.
AU - Srour, M.
AU - Turgeon-Desilet, S.
AU - Zielinski, D.
AU - Selby, K.
AU - King, C.
AU - Lee, J.
AU - Michoulas, A.
AU - Roland, E.
AU - Vajsar, J.
AU - Chau, V.
AU - Dowling, J.
AU - Haldenby, R.
AU - Miki, M.
AU - So, S.
AU - Pascual Pascual, S. I.
AU - Martinez Bermejo, A.
AU - Epinosa Garcia, S.
AU - Garcia Guixot, S.
AU - Martinez Moreno, M. M.
AU - del Pilar Tirado Requero, M.
AU - del Mar Garcia Romero, M.
AU - Aguilar, C.
AU - Munell Casadesus, F.
AU - Gomez Garcia de la Banda, M. B.
AU - Gallardo, M.
AU - Gili, G.
AU - Alavarez Molinero, M.
AU - de Los Angeles Tormos Munoz, M.
AU - Palacios, N. J.
AU - Planas Pascual, B.
AU - del Mar Melendez Plumed, M.
AU - Rucian, A. F.
AU - Toro Tamargo, E.
AU - Gratacos Vinola, M.
AU - Borell, S.
AU - Eckenweiler, M.
AU - Krüger, M.
AU - Pechmann, A.
AU - Rippberger, B.
AU - Stein, S.
AU - Vogt, S.
AU - Wider, S.
AU - Schara, U.
AU - Andres, B.
AU - Della Marina, A.
AU - Ganfuss, A.
AU - Jachertz, P.
AU - Koelbel, H.
AU - Rupprich, K.
AU - Schroers, E. S.
AU - Sponemann, N.
AU - Bruno, C.
AU - Fiorillo, C.
AU - Garaventa, A.
AU - Lanteri, P.
AU - Lanzillotta, V.
AU - Manzitti, C.
AU - Pedermonte, M.
AU - Tacchetti, P.
AU - Trucco, F.
AU - Zuffi, A.
AU - De Sanctis, R.
AU - Fanelli, L.
AU - Luigetti, M.
AU - Palermo, C.
AU - Pane, M.
AU - Piastra, M.
AU - Sivo, S.
AU - Gargaun, E.
AU - Gidaro, T.
AU - Gilabert, S.
AU - Léger, P. L.
AU - Le Moing, A. G.
AU - Lilien, C.
AU - Mayer, M.
AU - Ollievier, Q.
AU - Rambaud, J.
AU - Taytard, J.
AU - Vialle, R.
AU - Voit, T.
AU - Muntoni, F.
AU - D'Argenzio, L.
AU - Lister, PH
AU - Manzur, A.
AU - Pisco Domingos, J.
AU - Ramsey, D.
AU - Ricotti, V.
AU - Schottlaender, L.
AU - Scoto, M.
AU - Scuplak, S. M.
AU - Selby, V.
AU - Straub, V.
AU - Baily, S.
AU - Bertoli, M.
AU - Mayhew, A. G.
AU - Lofra, R. M.
AU - Murphy, A.
AU - Wood, C.
AU - Darin, N.
AU - Eldblom, J.
AU - Kimber, E.
AU - Kroksmark, A. K.
AU - Lindstedt, A.
AU - Michael, E.
AU - Sofou, K.
AU - Deconinck, N.
AU - Christiaens, A.
AU - Coppens, S.
AU - DeCock, K.
AU - De Vos voor, E.
AU - Dorban, F.
AU - Gilbert, G.
AU - Rooze, S.
AU - Tahon, V.
AU - Van Coster, R.
AU - Van Der Looven, R.
AU - Vanlander, A.
AU - Vens, D.
AU - Verhelst, H.
AU - Wenderickx, B.
AU - Wittevrongel, S.
AU - Farrar, M.
AU - Berthon-Jones, N.
AU - Doumit, M. A.
AU - Herbert, K. J.
AU - Kandula, T.
AU - Morrison, M.
AU - O'Brien, J.
AU - Richardson, S.
AU - Ferreira Sampaio, H. A.
AU - Teoh, H. L.
AU - Ryan, M.
AU - Carroll, K. M.
AU - De Valle, K. L.
AU - Villano, D.
AU - Woodcock, I.
AU - Yiu, E. M.
AU - Ardicli, D.
AU - Gunbey, C.
AU - Haliloglu, V. G.
AU - Karaduman, A. A.
AU - Konuskan, B.
AU - Yildiz Sarikaya, F. G.
AU - Serdaroglu, E.
AU - Tanyildiz, M.
AU - Temucin, C. M.
AU - Yildirim, M.
AU - Yilmaz, O. T.
AU - Arakawa, R.
AU - Chiba, Y.
AU - Eto, K.
AU - Hirasawa, K.
AU - Ikai, T.
AU - Ito, S.
AU - Ito, Y.
AU - Kaburagi, Y.
AU - Kaneko, H.
AU - Matsumaru, S.
AU - Matsushima, N.
AU - Mizuochi, K.
AU - Nagata, S.
AU - Nakatsukasa, H.
AU - Nishikawa, A.
AU - Otani, Y.
AU - Sato, T.
AU - Shichiji, M.
AU - Sugimoto, K.
AU - Takeshita, A.
AU - Yanagishita, T.
AU - Yamauchi, A.
AU - Takeshima, Y.
AU - Fujino, T.
AU - Fukuda, N.
AU - Lee, T.
AU - Oriyama, K.
AU - Shibano, T.
AU - Shimomura, H.
AU - Tachikawa, T.
AU - Tanaka, Y.
AU - Taniguchi, N.
AU - Chae, J. H.
AU - Choi, S. A.
AU - Chun, S. M.
AU - Jo, H.
AU - Kim, H.
AU - Kim, S. Y.
AU - Lee, J. S.
AU - Lim, B. C.
AU - Shin, H. I.
AU - Son, W. S.
AU - Chan, S.
AU - Chung, A. C.
AU - Yan, C. S.
AU - Stella, C.
AU - Joseph, C. K.W.
AU - Ng, C. S.
AU - Alvin, H. C.C.
AU - Janice, I. J.K.
AU - Wendy, L. W.M.
AU - Chui-San, M. N.
AU - Ki, N. Y.
AU - Shun, T. N.
AU - Connie, W. Y.
AU - Virginia, W. C.
AU - Yvonne, Y.
AU - Jong, Y. J.
AU - Chen, T. H.
AU - Chou, P. C.
AU - Chou, Y. H.
AU - Chung, H. W.
AU - Hsu, J. H.
AU - Ju, Y. H.
AU - Liang, W. C.
AU - Shih, H. H.
AU - Wang, H. Y.
AU - Wu, Y. C.
AU - Zeng, Y. S.
N1 - Funding Information: Supported by Biogen and Ionis Pharmaceuticals. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org. We thank the patients who participated in the trial and their parents, guardians, and family members; all contributors to the trial, including the clinical monitors, trial coordinators, physical therapists, pharmacists, laboratory technicians, and members of patient advocacy groups (who assisted in promoting awareness of the trial); Allison Green from Excel Scientific Solutions for providing writing assistance with earlier versions of the manuscript according to input from authors; and Jacqueline Atkinson from Excel Scientific Solutions for copy editing an earlier version of the manuscript. Publisher Copyright: Copyright © 2017 Massachusetts Medical Society.
PY - 2017/11/2
Y1 - 2017/11/2
N2 - BACKGROUND: Spinal muscular atrophy is an autosomal recessive neuromuscular disorder that is caused by an insufficient level of survival motor neuron (SMN) protein. Nusinersen is an antisense oligonucleotide drug that modifies pre–messenger RNA splicing of the SMN2 gene and thus promotes increased production of full-length SMN protein. METHODS: We conducted a randomized, double-blind, sham-controlled, phase 3 efficacy and safety trial of nusinersen in infants with spinal muscular atrophy. The primary end points were a motor-milestone response (defined according to results on the Hammersmith Infant Neurological Examination) and event-free survival (time to death or the use of permanent assisted ventilation). Secondary end points included overall survival and subgroup analyses of event-free survival according to disease duration at screening. Only the first primary end point was tested in a prespecified interim analysis. To control the overall type I error rate at 0.05, a hierarchical testing strategy was used for the second primary end point and the secondary end points in the final analysis. RESULTS: In the interim analysis, a significantly higher percentage of infants in the nusinersen group than in the control group had a motor-milestone response (21 of 51 infants [41%] vs. 0 of 27 [0%], P<0.001), and this result prompted early termination of the trial. In the final analysis, a significantly higher percentage of infants in the nusinersen group than in the control group had a motor-milestone response (37 of 73 infants [51%] vs. 0 of 37 [0%]), and the likelihood of event-free survival was higher in the nusinersen group than in the control group (hazard ratio for death or the use of permanent assisted ventilation, 0.53; P=0.005). The likelihood of overall survival was higher in the nusinersen group than in the control group (hazard ratio for death, 0.37; P=0.004), and infants with a shorter disease duration at screening were more likely than those with a longer disease duration to benefit from nusinersen. The incidence and severity of adverse events were similar in the two groups. CONCLUSIONS: Among infants with spinal muscular atrophy, those who received nusinersen were more likely to be alive and have improvements in motor function than those in the control group. Early treatment may be necessary to maximize the benefit of the drug.
AB - BACKGROUND: Spinal muscular atrophy is an autosomal recessive neuromuscular disorder that is caused by an insufficient level of survival motor neuron (SMN) protein. Nusinersen is an antisense oligonucleotide drug that modifies pre–messenger RNA splicing of the SMN2 gene and thus promotes increased production of full-length SMN protein. METHODS: We conducted a randomized, double-blind, sham-controlled, phase 3 efficacy and safety trial of nusinersen in infants with spinal muscular atrophy. The primary end points were a motor-milestone response (defined according to results on the Hammersmith Infant Neurological Examination) and event-free survival (time to death or the use of permanent assisted ventilation). Secondary end points included overall survival and subgroup analyses of event-free survival according to disease duration at screening. Only the first primary end point was tested in a prespecified interim analysis. To control the overall type I error rate at 0.05, a hierarchical testing strategy was used for the second primary end point and the secondary end points in the final analysis. RESULTS: In the interim analysis, a significantly higher percentage of infants in the nusinersen group than in the control group had a motor-milestone response (21 of 51 infants [41%] vs. 0 of 27 [0%], P<0.001), and this result prompted early termination of the trial. In the final analysis, a significantly higher percentage of infants in the nusinersen group than in the control group had a motor-milestone response (37 of 73 infants [51%] vs. 0 of 37 [0%]), and the likelihood of event-free survival was higher in the nusinersen group than in the control group (hazard ratio for death or the use of permanent assisted ventilation, 0.53; P=0.005). The likelihood of overall survival was higher in the nusinersen group than in the control group (hazard ratio for death, 0.37; P=0.004), and infants with a shorter disease duration at screening were more likely than those with a longer disease duration to benefit from nusinersen. The incidence and severity of adverse events were similar in the two groups. CONCLUSIONS: Among infants with spinal muscular atrophy, those who received nusinersen were more likely to be alive and have improvements in motor function than those in the control group. Early treatment may be necessary to maximize the benefit of the drug.
UR - http://www.scopus.com/inward/record.url?scp=85032714516&partnerID=8YFLogxK
U2 - 10.1056/NEJMoa1702752
DO - 10.1056/NEJMoa1702752
M3 - Article
C2 - 29091570
AN - SCOPUS:85032714516
SN - 0028-4793
VL - 377
SP - 1723
EP - 1732
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 18
ER -